SGLT2 Inhibitors and Cancer: What's the Risk?

February 3, 2015

The 3 FDA-approved sodium glucose co-transporter 2 inhibitors remain under close post-marketing scrutiny. These 7 slides distill for you all the cancer risk information to date.

There are 3 sodium glucose co-transporter 2 inhibitors approved for use in the US in patients with type 2 diabetes. Dapagliflozin, canagliflozin, and empagliflozin have all come under increased FDA scrutiny for potential carcinogenicity and manufacturers are engaged in mandatory post-marketing studies to further current understanding.The brief slide show above distills the clinical data on cancer risk for the 3 SGLT2 inhibitors. References for all slides are provided below.

References: